See today's BioWorld
To read the full story, subscribe or sign in.

Unity shares untied as osteoarthritis of the knee drug fails phase II test

Aug. 17, 2020
By Michael Fitzhugh
Shares of Unity Biotechnology Inc. (NASDAQ:UBX) fell 66.6% to $4.15 on Aug. 17 after UBX-0101, its one-time lead candidate, failed to best a placebo on an established measure of osteoarthritis pain in a phase II study.
BioWorld Clinical Inflammatory